You are here

Article Text

Article menu

Download PDFPDF

Scientific Abstracts
Publication Only
COVID-19
AB1101 PREVALENCE OF LONG COVID IN RHEUMATIC DISEASE PATIENTS: ANALYSIS OF SAR COVID REGISTRY
Free
  1. C. A. Gonzalez Gomez1,
  2. M. Cosatti1,
  3. V. V. Castro Coello2,
  4. M. Haye2,
  5. Y. Tissera2,
  6. A. A. Reyes2,
  7. J. A. Albiero2,
  8. S. Ornella2,
  9. P. Alba2,
  10. C. Gobbi2,
  11. M. J. Gamba2,
  12. I. E. Exeni2,
  13. A. Cusa2,
  14. J. Gallino Yanzi2,
  15. V. I. Bellomio2,
  16. G. Gomez2,
  17. D. Zelaya2,
  18. L. Takashima2,
  19. L. Carlevaris2,
  20. M. D. L. A. Correa2,
  21. R. Rojas Tessel2,
  22. M. García2,
  23. N. German2,
  24. A. L. Mercé2,
  25. A. Bertoli2,
  26. S. E. Aguero2,
  27. M. E. Calvo2,
  28. V. Martire2,
  29. M. Mauri2,
  30. M. L. Martin2,
  31. E. Picco2,
  32. D. Castrillon Bustamante2,
  33. L. Ibañez Zurlo2,
  34. M. N. Tamborenea2,
  35. G. C. Subils2,
  36. D. L. Vasquez2,
  37. S. Soares de Souza2,
  38. N. Herscovich2,
  39. L. Raiti2,
  40. V. Cosentino2,
  41. F. Rodriguez2,
  42. C. Ledesma2,
  43. M. P. Diaz2,
  44. M. L. Mamani Ortega2,
  45. M. S. Castaño2,
  46. G. Gómez2,
  47. K. Roberts2,
  48. R. Quintana2,
  49. C. A. Isnardi2,
  50. G. Pons-Estel2,
  51. C. Pisoni1
  1. 1CEMIC, Centro de Educación Médica e Investigaciones Clínicas Norberto Quirno, Rheumatology Section, Ciudad de Buenos Aires, Argentina
  2. 2on behalf of SAR COVID Registry, SAR Research Unit, Ciudad de Buenos Aires, Argentina

Abstract

Background Persistent symptoms after acute COVID have been described previously. Main symptoms reported are fatigue, arthralgias, myalgias and mental sickness. Definition and methods vary widely.1

Objectives To asses prevalence and related factors to long COVID in a retrospective cohort of patients with rheumatic diseases from Argentina.

Methods A total of 1915 patients were registered from August 18th, 2020 to July 29th, 2021. Patients > 18 years old, with rheumatic disease and confirmed infection by SARS-CoV-2 (antigen or RT-PCR) were included. Those dead, with unknown outcome, wrong date or missing data were excluded. Demographic data, comorbidities, rheumatic disease, and characteristics of SARS-CoV-2 infection were recorded.

Long COVID was defined according to NICE guidelines (persistent symptoms for more than 4 weeks, without alternative diagnosis). Long COVID symptoms were defined by rheumatologist. Severity of infection was classified according to WHO ordinal scale.

We used descriptive statistics, univariate model (Student’s test, chi square test, ANOVA) and multivariate logistic regression analysis.

Results 230 (12%) had long COVID. Median age was 51 (IQR 40-61]) years, 82% were females, 51% were not caucasian. Median of education was 13.3 years (IQR 12 – 16), 79 % had private health insurance and 55 % were employed. Nearly half (n=762, 46%) had comorbidities, the most prevalent was hypertension (n=396, 24%).

The most frequent rheumatic diseases were rheumatoid arthritis (n=719, 42%) and systemic lupus erythematosus (n=280, 16 %). Most were in low activity/remission (79%), used Conventional DMARD (n=773 patients, 45%) and steroids (n=588, 34%) at low dose (n=415, 71%).

Main laboratory findings were abnormal D-dimer (n=94, 28%) and leukopenia (n=93, 26%). Most patients had a WHO ordinal scale < 5 (n=1472, 86%). Median of hospitalization at intensive care unit (ICU) was 8 days [IQR 5, 13]. Treatment for SARS-CoV-2 infection (steroids, anticoagulation, azithromycin, convalescent plasma) was used in 461 (27%) patients.

Most of long COVID (n= 152, 69%) reported 1 symptom, the most frequent was fatigue (n= 55, 22%). Figure 1.

Univariate analysis is presented in Table 1. In multivariate logistic regression analysis non-caucasian ethnicity OR 1.44 (1.07-1.95), years of education OR 1.05 (1-1.09), treatment with cyclophosphamide OR 11.35 (1.56-112.97), symptoms of COVID – 19 OR 13.26 (2.75-242.08), severity scale WHO ≥ 5 OR 2.46 (1.68-3.57), and ICU hospitalization days OR 1.09 (1.05-1.14) were factors associated to long COVID.

View this table:
Table 1.

Univariate analysis of long COVID syndrome in SAR – COVID registry

Figure

Conclusion Prevalence of long COVID was 12%. Non-caucasian ethnicity, higher education, treatment with cyclophosphamide, symptoms of COVID – 19, severe disease and ICU hospitalization days were related to long COVID.

References [1]Cabrera Martimbianco AL, Pacheco RL, Bagattini ÂM, Riera R. Frequency, signs and symptoms, and criteria adopted for long COVID-19: A systematic review. Int J Clin Pract.

Disclosure of Interests None declared

https://doi.org/10.1136/annrheumdis-2022-eular.1021

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.